Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−10.6 SEK
−123.07 M SEK
0.00 SEK
11.24 M
About INFANT BACTERIAL THERAPEUTICS AB SER. B
Sector
CEO
Staffan Strömberg
Headquarters
Stockholm
Website
Founded
2011
ISIN
SE0008015259
FIGI
BBG00CB3BRH4
Infant Bacterial Therapeutics AB is a clinical stage pharmaceutical company, which engages in the development of drugs for the treatment of rare diseases affecting premature infants. Its products include IBP-9414 and IBP-1016. The IBP-9414, is a drug candidate contains Lactobacillus reuteri which is a human bacterial strain naturally present in breast milk that improves feeding tolerance in premature infants and IBP-1016, helps in treating gastroschisis, a severe birth defect in infants. The company was founded in 2013 and is headquartered in Stockholm, Sweden.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of IBT_B is 56.0 SEK — it has decreased by −5.08% in the past 24 hours. Watch INFANT BACTERIAL THERAPEUTICS AB SER. B stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OMXSTO exchange INFANT BACTERIAL THERAPEUTICS AB SER. B stocks are traded under the ticker IBT_B.
IBT_B stock has risen by 6.46% compared to the previous week, the month change is a 47.37% rise, over the last year INFANT BACTERIAL THERAPEUTICS AB SER. B has showed a −36.36% decrease.
IBT_B reached its all-time high on Jul 5, 2019 with the price of 274.6 SEK, and its all-time low was 21.8 SEK and was reached on Sep 2, 2024. View more price dynamics on IBT_B chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
IBT_B stock is 16.60% volatile and has beta coefficient of 2.06. Track INFANT BACTERIAL THERAPEUTICS AB SER. B stock price on the chart and check out the list of the most volatile stocks — is INFANT BACTERIAL THERAPEUTICS AB SER. B there?
Today INFANT BACTERIAL THERAPEUTICS AB SER. B has the market capitalization of 754.40 M, it has increased by 10.07% over the last week.
Yes, you can track INFANT BACTERIAL THERAPEUTICS AB SER. B financials in yearly and quarterly reports right on TradingView.
INFANT BACTERIAL THERAPEUTICS AB SER. B is going to release the next earnings report on Feb 13, 2025. Keep track of upcoming events with our Earnings Calendar.
IBT_B net income for the last quarter is −32.65 M SEK, while the quarter before that showed −42.67 M SEK of net income which accounts for 23.49% change. Track more INFANT BACTERIAL THERAPEUTICS AB SER. B financial stats to get the full picture.
No, IBT_B doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 25, 2024, the company has 8.00 employees. See our rating of the largest employees — is INFANT BACTERIAL THERAPEUTICS AB SER. B on this list?
Like other stocks, IBT_B shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade INFANT BACTERIAL THERAPEUTICS AB SER. B stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So INFANT BACTERIAL THERAPEUTICS AB SER. B technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating INFANT BACTERIAL THERAPEUTICS AB SER. B stock shows the sell signal. See more of INFANT BACTERIAL THERAPEUTICS AB SER. B technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.